DCRI **NEUROSCIENCES MEDICINE**

Changing Tomorrow's Medicine Today

The DCRI is dedicated to advancing clinical research by promoting education, knowledge-sharing, scientifically designed studies, and operationally efficient clinical trial conduct. DCRI's Neurosciences Medicine Research Program, comprising more than 40 psychiatry and neurology faculty, supports this mission through innovative programs, vast expertise across multiple disciplines, and broad-reaching influence as leaders in academic, industry, and government roles.

We conduct industry and government-funded clinical projects of all sizes covering the full spectrum of neurosciences disorders, featuring projects in psychiatry and neurology for child, adolescent, adult, and geriatric patient populations. Our research interests and capabilities are wide-ranging and include a focus on ADHD, autism, mood and anxiety disorders, epilepsy, sleep disorders, neuromuscular disorders, stroke, and neurodegenerative diseases.

INNOVATION

- Rapid-Start Site Network for Neurosciences Trials
- Cognitive Endpoint Design and Assessment in Clinical Trials
- Control Intervention Development
- FAST-FAIL Trial Methodology
- Inpatient ICU Trials
- Neuroimmunology Biomarker Imaging Studies
- RDOC-based Research

EXPERTISE

- Early Phase PK/PD and POC Trials, conducted in our onsite Phase I unit
- Game and Device/Sham-Controlled Trial Design and Conduct
- Pediatrics (Microdosing, PK)
- Neurocritical Care Trials
- Electroencephalography (EEG)
- Polysomnography (PSG)
- Nerve conduction studies and electromyography
- Immune monitoring – mechanistic and predictive biomarkers
- Full-service CRO activities (Protocol Design/Development, Data Management, Biostatistics, Pharmacokinetics, Site Management Monitoring)

Influence

Our neuroscience experts have worked with the FDA many times for market approvals in drug, device, and diagnostic studies and are instrumental in creating and implementing new NIMH guidelines. Our faculty have published their research in major peer-reviewed journals and regularly present at national meetings, sharing knowledge and contributing to the formation of practice-changing innovations for tomorrow's medicine.

Recent Experience

33,000
neurosciences patients enrolled

1,100
neurosciences sites

50
neurosciences trials spanning all study phases, from animal models through post-market

DCRI **NEUROSCIENCES MEDICINE**

Find out more about DCRI Neurosciences Medicine.

Jennifer Hart
Assistant Director, Business Development Neurosciences Medicine
919-428-8101
jennifer.d.hart@duke.edu

dcri.org/neurosciences

OUR INVESTIGATOR NETWORKS

- National Child Traumatic Stress Network, a nationwide consortium of premier research institutes, hospitals, and healthcare providers focused on improving the care of traumatized children
- Child and Adolescent Psychiatry Trials Network (CAPTN), the first consortium of its kind focused on pediatric psychopharmacology
- Treatment for Adolescents with Depression Study (TADS)
- Multi-site, Multi-National Stroke Network

OUR FACULTY

Daniel Laskowitz, MD, MHS
Faculty Director, DCRI Neurosciences Medicine
Professor, Neurology
Professor, Neurobiology
Professor, Anesthesiology
Director, Neurovascular Laboratories

Aatif Husain, MD
Global Epilepsy and Sleep Program

Scott Kollins, PhD, MS
Associate Professor, Medical Psychology
Professor, Psychiatry and Behavioral Sciences
Professor, Psychology and Neuroscience
Vice-Chair for Research Strategy & Development
Director, Duke ADHD Program

Rich Keefe, PhD
Professor, Psychiatry and Behavioral Sciences
Professor, Psychology & Neuroscience

Brad Kolls, MD, PhD, MMCi
Assistant Professor, Neurology

Jeffrey Guptill, MD, MA, MHS
Assistant Professor, Neurology
Associate Director, Duke Clinical Research Unit

Linmarie Sikich, MD
Faculty Member, DCRI Neurosciences Medicine
Professor, Psychiatry and Behavioral Sciences
Associate Director, Duke Center for Autism and Brain Development

Duke Clinical Research Institute | FROM **THOUGHT LEADERSHIP** TO **CLINICAL PRACTICE**

Produced using paper from sustainable forests | DCRI Communications April 2017